| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 79 | 2003 | 5767 | 2.140 |
Why?
|
| Prostate-Specific Antigen | 44 | 2003 | 993 | 1.920 |
Why?
|
| Sarcoma | 30 | 2016 | 1725 | 1.780 |
Why?
|
| Soft Tissue Neoplasms | 14 | 2018 | 882 | 0.980 |
Why?
|
| Adenocarcinoma | 38 | 2003 | 7789 | 0.970 |
Why?
|
| Neoplasm Recurrence, Local | 57 | 2018 | 10035 | 0.870 |
Why?
|
| Radiotherapy, Adjuvant | 22 | 2018 | 2231 | 0.840 |
Why?
|
| Skin Neoplasms | 12 | 2013 | 4654 | 0.820 |
Why?
|
| Orchiectomy | 14 | 2004 | 214 | 0.790 |
Why?
|
| Combined Modality Therapy | 67 | 2018 | 8865 | 0.710 |
Why?
|
| Radiotherapy Dosage | 40 | 2015 | 3842 | 0.650 |
Why?
|
| Testicular Neoplasms | 8 | 2004 | 529 | 0.650 |
Why?
|
| Melanoma | 10 | 2013 | 5317 | 0.630 |
Why?
|
| Radiotherapy, High-Energy | 14 | 2003 | 295 | 0.570 |
Why?
|
| Dysgerminoma | 6 | 1993 | 42 | 0.530 |
Why?
|
| Aged | 121 | 2018 | 70117 | 0.520 |
Why?
|
| Analysis of Variance | 20 | 2008 | 2307 | 0.520 |
Why?
|
| Androgen Antagonists | 6 | 2002 | 411 | 0.510 |
Why?
|
| Actuarial Analysis | 19 | 2004 | 159 | 0.500 |
Why?
|
| Middle Aged | 127 | 2018 | 86204 | 0.490 |
Why?
|
| Aged, 80 and over | 63 | 2018 | 29902 | 0.490 |
Why?
|
| Male | 157 | 2018 | 123000 | 0.480 |
Why?
|
| Dermatofibrosarcoma | 2 | 2013 | 72 | 0.480 |
Why?
|
| Lymphatic Metastasis | 22 | 2011 | 4844 | 0.460 |
Why?
|
| Follow-Up Studies | 51 | 2018 | 14889 | 0.460 |
Why?
|
| Prognosis | 61 | 2018 | 21713 | 0.420 |
Why?
|
| Disease-Free Survival | 23 | 2018 | 10001 | 0.390 |
Why?
|
| Neoplasm Staging | 45 | 2018 | 13658 | 0.370 |
Why?
|
| Adult | 88 | 2018 | 77950 | 0.360 |
Why?
|
| Testosterone | 4 | 1998 | 619 | 0.350 |
Why?
|
| Seminoma | 3 | 2004 | 81 | 0.350 |
Why?
|
| Phyllodes Tumor | 3 | 2000 | 62 | 0.350 |
Why?
|
| Retrospective Studies | 56 | 2018 | 37905 | 0.340 |
Why?
|
| Humans | 175 | 2018 | 261506 | 0.340 |
Why?
|
| Lymphatic Irradiation | 2 | 2008 | 133 | 0.340 |
Why?
|
| Treatment Outcome | 49 | 2018 | 32848 | 0.330 |
Why?
|
| Dose-Response Relationship, Radiation | 13 | 2004 | 726 | 0.330 |
Why?
|
| Survival Rate | 32 | 2018 | 12221 | 0.330 |
Why?
|
| Reoperation | 2 | 2003 | 1382 | 0.330 |
Why?
|
| Salvage Therapy | 8 | 2018 | 2054 | 0.320 |
Why?
|
| Head and Neck Neoplasms | 3 | 2013 | 3976 | 0.300 |
Why?
|
| Biomarkers, Tumor | 18 | 2003 | 10331 | 0.290 |
Why?
|
| Time Factors | 33 | 2008 | 12926 | 0.290 |
Why?
|
| Adolescent | 44 | 2018 | 31252 | 0.270 |
Why?
|
| Lymph Node Excision | 7 | 2011 | 1959 | 0.270 |
Why?
|
| Carcinoma, Transitional Cell | 9 | 1997 | 962 | 0.240 |
Why?
|
| Retroperitoneal Neoplasms | 4 | 2015 | 262 | 0.240 |
Why?
|
| Lower Extremity | 3 | 2016 | 299 | 0.230 |
Why?
|
| Radiotherapy | 13 | 2018 | 1824 | 0.230 |
Why?
|
| Female | 76 | 2018 | 141928 | 0.230 |
Why?
|
| Neoplasm Metastasis | 18 | 2009 | 5112 | 0.220 |
Why?
|
| Sarcoma, Synovial | 3 | 2007 | 119 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 11 | 1997 | 2341 | 0.220 |
Why?
|
| Fibromatosis, Aggressive | 4 | 2008 | 109 | 0.220 |
Why?
|
| Radiation Injuries | 9 | 2008 | 1411 | 0.220 |
Why?
|
| Multivariate Analysis | 16 | 2010 | 4298 | 0.200 |
Why?
|
| Organ Sparing Treatments | 2 | 2015 | 277 | 0.200 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2001 | 73 | 0.190 |
Why?
|
| Liposarcoma | 3 | 2015 | 214 | 0.190 |
Why?
|
| Acid Phosphatase | 7 | 1999 | 59 | 0.180 |
Why?
|
| Survival Analysis | 19 | 2018 | 9180 | 0.180 |
Why?
|
| Extremities | 5 | 2007 | 303 | 0.180 |
Why?
|
| Ploidies | 5 | 1999 | 248 | 0.180 |
Why?
|
| Regression Analysis | 9 | 2007 | 1546 | 0.180 |
Why?
|
| Prostatectomy | 10 | 1999 | 962 | 0.170 |
Why?
|
| Neurofibrosarcoma | 1 | 2018 | 33 | 0.160 |
Why?
|
| Child | 25 | 2015 | 29154 | 0.160 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2018 | 44 | 0.150 |
Why?
|
| Cystectomy | 8 | 1997 | 623 | 0.150 |
Why?
|
| Young Adult | 8 | 2018 | 21445 | 0.150 |
Why?
|
| Limb Salvage | 2 | 2015 | 162 | 0.140 |
Why?
|
| Femoral Fractures | 1 | 2016 | 50 | 0.140 |
Why?
|
| DNA, Neoplasm | 4 | 1999 | 1910 | 0.140 |
Why?
|
| Child, Preschool | 12 | 2008 | 16273 | 0.130 |
Why?
|
| Bone Neoplasms | 6 | 2015 | 2576 | 0.130 |
Why?
|
| Hand Bones | 1 | 2015 | 8 | 0.130 |
Why?
|
| Foot Diseases | 1 | 2015 | 52 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2006 | 3890 | 0.120 |
Why?
|
| Antigens, Neoplasm | 2 | 1992 | 1506 | 0.120 |
Why?
|
| Texas | 5 | 2018 | 6311 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 383 | 0.120 |
Why?
|
| Misonidazole | 2 | 1985 | 11 | 0.120 |
Why?
|
| Testis | 1 | 1998 | 717 | 0.120 |
Why?
|
| Prostate | 6 | 1998 | 1088 | 0.120 |
Why?
|
| Clinical Trials as Topic | 6 | 2009 | 3719 | 0.110 |
Why?
|
| Anus Neoplasms | 2 | 2011 | 411 | 0.110 |
Why?
|
| Liposarcoma, Myxoid | 2 | 2007 | 38 | 0.110 |
Why?
|
| Diethylstilbestrol | 2 | 1995 | 109 | 0.110 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 1999 | 167 | 0.110 |
Why?
|
| Kinetics | 5 | 1997 | 2049 | 0.110 |
Why?
|
| Cryptorchidism | 1 | 1992 | 40 | 0.100 |
Why?
|
| Doxorubicin | 5 | 2004 | 3005 | 0.100 |
Why?
|
| Urinary Bladder | 4 | 2000 | 575 | 0.100 |
Why?
|
| Radiography | 3 | 2008 | 1904 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 4 | 2000 | 902 | 0.100 |
Why?
|
| Preoperative Care | 4 | 2006 | 1529 | 0.100 |
Why?
|
| Ki-67 Antigen | 3 | 2003 | 666 | 0.100 |
Why?
|
| Age Factors | 6 | 2018 | 5377 | 0.090 |
Why?
|
| Recurrence | 5 | 2001 | 4758 | 0.090 |
Why?
|
| Anal Canal | 1 | 2011 | 238 | 0.090 |
Why?
|
| Lymph Nodes | 3 | 2011 | 2967 | 0.090 |
Why?
|
| Facial Neoplasms | 1 | 2010 | 84 | 0.090 |
Why?
|
| Jaw Neoplasms | 1 | 2009 | 17 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2013 | 1987 | 0.090 |
Why?
|
| Thoracic Neoplasms | 2 | 2007 | 337 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2004 | 726 | 0.090 |
Why?
|
| Rectal Neoplasms | 2 | 2011 | 1202 | 0.090 |
Why?
|
| Scalp | 1 | 2010 | 156 | 0.080 |
Why?
|
| Cohort Studies | 10 | 2018 | 9244 | 0.080 |
Why?
|
| Osteosarcoma | 2 | 2009 | 929 | 0.080 |
Why?
|
| Hodgkin Disease | 3 | 1986 | 1429 | 0.080 |
Why?
|
| Treatment Failure | 5 | 2007 | 1391 | 0.080 |
Why?
|
| Hemangiosarcoma | 1 | 2010 | 234 | 0.080 |
Why?
|
| Axilla | 2 | 2008 | 902 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2012 | 621 | 0.080 |
Why?
|
| Laparotomy | 2 | 1985 | 211 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 5 | 1994 | 1581 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 5687 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2003 | 665 | 0.070 |
Why?
|
| Periosteum | 1 | 2007 | 39 | 0.070 |
Why?
|
| Infant | 6 | 2004 | 13310 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2010 | 739 | 0.070 |
Why?
|
| Retinoblastoma Protein | 2 | 1997 | 335 | 0.070 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 884 | 0.070 |
Why?
|
| Abdominal Neoplasms | 1 | 1988 | 231 | 0.070 |
Why?
|
| Retreatment | 1 | 2007 | 452 | 0.070 |
Why?
|
| Diploidy | 2 | 1997 | 114 | 0.070 |
Why?
|
| Medical Records | 2 | 2006 | 415 | 0.070 |
Why?
|
| Breast Neoplasms | 4 | 2000 | 15694 | 0.070 |
Why?
|
| Risk Factors | 4 | 2016 | 17523 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 9 | 2018 | 3981 | 0.060 |
Why?
|
| Brachytherapy | 4 | 2007 | 977 | 0.060 |
Why?
|
| Apoptosis | 5 | 2000 | 7591 | 0.060 |
Why?
|
| Neoplasm, Residual | 4 | 2015 | 1656 | 0.060 |
Why?
|
| Life Tables | 1 | 2003 | 120 | 0.060 |
Why?
|
| Ultrasonography | 4 | 2000 | 1863 | 0.060 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2003 | 52 | 0.060 |
Why?
|
| Hand | 2 | 2002 | 170 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 450 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 1998 | 1363 | 0.050 |
Why?
|
| S Phase | 3 | 1999 | 281 | 0.050 |
Why?
|
| Half-Life | 2 | 1997 | 259 | 0.050 |
Why?
|
| Erectile Dysfunction | 3 | 2003 | 212 | 0.050 |
Why?
|
| Proportional Hazards Models | 7 | 2002 | 4988 | 0.050 |
Why?
|
| Spermatic Cord | 1 | 2001 | 14 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 2 | 2002 | 341 | 0.050 |
Why?
|
| Genital Neoplasms, Male | 1 | 2001 | 44 | 0.050 |
Why?
|
| Nitroimidazoles | 1 | 1982 | 100 | 0.050 |
Why?
|
| Prospective Studies | 7 | 2007 | 12873 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2003 | 447 | 0.050 |
Why?
|
| Rectum | 2 | 2000 | 467 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2001 | 344 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2003 | 225 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1985 | 363 | 0.050 |
Why?
|
| Minisatellite Repeats | 1 | 2000 | 51 | 0.050 |
Why?
|
| Urination Disorders | 2 | 1998 | 61 | 0.050 |
Why?
|
| Cause of Death | 1 | 2004 | 752 | 0.050 |
Why?
|
| Biopsy | 3 | 2012 | 3443 | 0.040 |
Why?
|
| Palpation | 2 | 2000 | 49 | 0.040 |
Why?
|
| Predictive Value of Tests | 6 | 2002 | 4892 | 0.040 |
Why?
|
| Seminal Vesicles | 1 | 1998 | 152 | 0.040 |
Why?
|
| Dihydrotestosterone | 1 | 1998 | 118 | 0.040 |
Why?
|
| Luteinizing Hormone | 1 | 1998 | 165 | 0.040 |
Why?
|
| Fibrosis | 1 | 2001 | 793 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 588 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 915 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 1997 | 86 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2004 | 732 | 0.040 |
Why?
|
| Carcinoma | 2 | 2003 | 2578 | 0.040 |
Why?
|
| Intestinal Diseases | 1 | 1998 | 121 | 0.040 |
Why?
|
| Polyploidy | 1 | 1997 | 73 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2003 | 2594 | 0.040 |
Why?
|
| Melphalan | 3 | 1990 | 834 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1997 | 342 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1997 | 369 | 0.030 |
Why?
|
| Endosonography | 1 | 1999 | 536 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 1493 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 980 | 0.030 |
Why?
|
| Hematuria | 2 | 2003 | 85 | 0.030 |
Why?
|
| Hand Dermatoses | 1 | 2015 | 25 | 0.030 |
Why?
|
| Foot Dermatoses | 1 | 2015 | 23 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 1350 | 0.030 |
Why?
|
| Vaginal Neoplasms | 1 | 1996 | 152 | 0.030 |
Why?
|
| Flutamide | 1 | 1995 | 40 | 0.030 |
Why?
|
| Movement | 1 | 1998 | 556 | 0.030 |
Why?
|
| Muscle Neoplasms | 1 | 1996 | 109 | 0.030 |
Why?
|
| Whole-Body Irradiation | 4 | 1994 | 307 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6207 | 0.030 |
Why?
|
| Radiodermatitis | 1 | 2015 | 75 | 0.030 |
Why?
|
| Mass Screening | 1 | 2003 | 1509 | 0.030 |
Why?
|
| Neutrons | 1 | 1995 | 117 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 1997 | 3552 | 0.030 |
Why?
|
| Linear Models | 1 | 1997 | 1085 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1999 | 840 | 0.030 |
Why?
|
| Mastectomy | 1 | 2000 | 1534 | 0.030 |
Why?
|
| Drug Evaluation | 2 | 1985 | 425 | 0.030 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1993 | 51 | 0.030 |
Why?
|
| Urethral Neoplasms | 1 | 1993 | 60 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1996 | 5437 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 1993 | 130 | 0.030 |
Why?
|
| Probability | 1 | 1995 | 866 | 0.030 |
Why?
|
| Pelvis | 3 | 2004 | 362 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 1999 | 2370 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 2139 | 0.030 |
Why?
|
| Flow Cytometry | 5 | 1997 | 3033 | 0.030 |
Why?
|
| Piperazines | 2 | 1994 | 2101 | 0.030 |
Why?
|
| Forecasting | 1 | 1994 | 694 | 0.030 |
Why?
|
| Immunohistochemistry | 5 | 2003 | 7548 | 0.030 |
Why?
|
| Wound Healing | 2 | 2006 | 815 | 0.020 |
Why?
|
| Logistic Models | 1 | 1998 | 3441 | 0.020 |
Why?
|
| Statistics as Topic | 3 | 2004 | 445 | 0.020 |
Why?
|
| Muscle, Smooth | 3 | 1997 | 236 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1995 | 1090 | 0.020 |
Why?
|
| DNA | 2 | 2000 | 2693 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1990 | 112 | 0.020 |
Why?
|
| Cisplatin | 2 | 1988 | 2432 | 0.020 |
Why?
|
| Rectal Diseases | 3 | 1996 | 55 | 0.020 |
Why?
|
| Fibroma | 1 | 1990 | 85 | 0.020 |
Why?
|
| Quality of Life | 1 | 2003 | 4532 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1990 | 193 | 0.020 |
Why?
|
| Amifostine | 2 | 1986 | 97 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 1000 | 0.020 |
Why?
|
| Splenectomy | 2 | 1986 | 158 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2002 | 15862 | 0.020 |
Why?
|
| Proctitis | 1 | 1987 | 18 | 0.020 |
Why?
|
| Mutation | 2 | 2000 | 15179 | 0.020 |
Why?
|
| Disease Progression | 2 | 1997 | 6682 | 0.020 |
Why?
|
| Medicare | 1 | 2012 | 860 | 0.020 |
Why?
|
| Multiple Myeloma | 2 | 1990 | 2138 | 0.020 |
Why?
|
| Urination | 1 | 1987 | 36 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 1994 | 1547 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 1987 | 44 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1986 | 684 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1993 | 1271 | 0.020 |
Why?
|
| Incidence | 2 | 1994 | 5673 | 0.020 |
Why?
|
| Organothiophosphorus Compounds | 1 | 1986 | 5 | 0.020 |
Why?
|
| Methotrexate | 1 | 1990 | 999 | 0.020 |
Why?
|
| Random Allocation | 1 | 1988 | 703 | 0.020 |
Why?
|
| Cystitis | 1 | 1987 | 107 | 0.020 |
Why?
|
| Neoplasms | 3 | 1987 | 15193 | 0.020 |
Why?
|
| Radiation Protection | 1 | 1987 | 205 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 1382 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 1987 | 189 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 1986 | 128 | 0.020 |
Why?
|
| Biomarkers | 1 | 1997 | 5047 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1997 | 3230 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 417 | 0.020 |
Why?
|
| Creatinine | 1 | 1987 | 531 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2000 | 1519 | 0.020 |
Why?
|
| Microsurgery | 1 | 2007 | 244 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2007 | 467 | 0.020 |
Why?
|
| Rats | 3 | 2000 | 6086 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 6869 | 0.020 |
Why?
|
| Cell Division | 2 | 2000 | 2489 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2006 | 291 | 0.010 |
Why?
|
| Spinal Cord | 1 | 1987 | 690 | 0.010 |
Why?
|
| Pain, Intractable | 1 | 1985 | 171 | 0.010 |
Why?
|
| Nausea | 1 | 1985 | 525 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 580 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2003 | 196 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2003 | 149 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1994 | 2527 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2003 | 367 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1993 | 4078 | 0.010 |
Why?
|
| Cell Count | 2 | 1997 | 508 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1945 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2003 | 259 | 0.010 |
Why?
|
| Lymphoma | 2 | 1987 | 1467 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2003 | 203 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1986 | 2358 | 0.010 |
Why?
|
| Graft vs Host Disease | 2 | 1990 | 2638 | 0.010 |
Why?
|
| Lymphedema | 1 | 2004 | 239 | 0.010 |
Why?
|
| United States | 2 | 2012 | 15433 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1985 | 1544 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1986 | 941 | 0.010 |
Why?
|
| Arm | 1 | 2002 | 147 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1982 | 573 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 5395 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 1290 | 0.010 |
Why?
|
| Cell Survival | 1 | 1987 | 3045 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 340 | 0.010 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1986 | 598 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 2796 | 0.010 |
Why?
|
| Edema | 1 | 2002 | 267 | 0.010 |
Why?
|
| Diarrhea | 1 | 2003 | 686 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1987 | 3001 | 0.010 |
Why?
|
| Models, Biological | 1 | 1987 | 3254 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 2001 | 406 | 0.010 |
Why?
|
| Castration | 1 | 1997 | 122 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1982 | 500 | 0.010 |
Why?
|
| Palliative Care | 3 | 1986 | 2037 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1999 | 297 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1997 | 162 | 0.010 |
Why?
|
| Radioisotope Teletherapy | 1 | 1996 | 12 | 0.010 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1999 | 221 | 0.010 |
Why?
|
| Inguinal Canal | 1 | 1996 | 60 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 1999 | 429 | 0.010 |
Why?
|
| Urinary Bladder Diseases | 1 | 1996 | 45 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2003 | 1162 | 0.010 |
Why?
|
| Platelet Count | 2 | 1986 | 490 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1994 | 6915 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 3203 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 2803 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 5542 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 2488 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1995 | 477 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1994 | 543 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 2403 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1997 | 1014 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1994 | 335 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 4320 | 0.010 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 14289 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1994 | 974 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2004 | 4975 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 1991 | 78 | 0.010 |
Why?
|
| Wrist | 1 | 1990 | 26 | 0.010 |
Why?
|
| Ankle | 1 | 1990 | 36 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 4557 | 0.010 |
Why?
|
| Foot | 1 | 1990 | 104 | 0.010 |
Why?
|
| Lung Neoplasms | 3 | 2007 | 11538 | 0.010 |
Why?
|
| Animals | 3 | 2000 | 59536 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 4917 | 0.010 |
Why?
|
| Cobalt Radioisotopes | 1 | 1987 | 42 | 0.000 |
Why?
|
| Clavicle | 1 | 1987 | 65 | 0.000 |
Why?
|
| Prednisone | 1 | 1990 | 984 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 6089 | 0.000 |
Why?
|
| Mathematics | 1 | 1987 | 136 | 0.000 |
Why?
|
| Blood Cells | 1 | 1987 | 127 | 0.000 |
Why?
|
| Algorithms | 1 | 1998 | 3890 | 0.000 |
Why?
|
| Bone and Bones | 1 | 1990 | 619 | 0.000 |
Why?
|
| Preservation, Biological | 1 | 1986 | 15 | 0.000 |
Why?
|
| Freezing | 1 | 1986 | 59 | 0.000 |
Why?
|
| Vincristine | 1 | 1990 | 1511 | 0.000 |
Why?
|
| Electrons | 1 | 1987 | 168 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1990 | 1914 | 0.000 |
Why?
|
| Granulocytes | 1 | 1986 | 224 | 0.000 |
Why?
|
| Intestines | 1 | 1990 | 686 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1990 | 1450 | 0.000 |
Why?
|
| Premedication | 1 | 1985 | 135 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1990 | 2315 | 0.000 |
Why?
|
| Karyotyping | 1 | 1986 | 1022 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1997 | 7222 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1998 | 7551 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1985 | 408 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1990 | 4938 | 0.000 |
Why?
|
| Philadelphia Chromosome | 1 | 1986 | 793 | 0.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1997 | 8873 | 0.000 |
Why?
|
| Risk | 1 | 1986 | 1972 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1987 | 2084 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1986 | 1242 | 0.000 |
Why?
|